Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.279E-15 | 2.020E-10 | CA12, CA2, CA4, CA5B, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.551E-12 | 3.866E-08 | CA12, CA2, CA4, CA5B, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.279E-11 | 9.281E-08 | CA12, CA2, CA4, CA5B, CA7, CA9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.936E-06 | 6.881E-03 | CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 2.937E-06 | 6.881E-03 | CA12, CA2, CA4, CA5B, CA7, CA9, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 8.048E-03 | CA2, CA7 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.860E-14 | 1.543E-12 | CA12; CA5B; CA2; CA4; CA7; CA9 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.192E-05 | 9.096E-04 | CASP7; LMNA; NFKB1; MCL1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.823E-05 | 9.309E-04 | CASP7; CASP1; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.486E-05 | 9.309E-04 | CYP1A2; CYP1B1; CYP3A4 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.316E-05 | 1.048E-03 | CYP1A2; ALDH1A1; CYP3A4 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.936E-05 | 1.149E-03 | CYP1A2; CYP1B1; CYP3A4 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 9.687E-05 | 1.149E-03 | CASP7; CASP1; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.263E-04 | 1.311E-03 | CYP1A2; CYP1B1; CYP3A4 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.035E-03 | 7.241E-03 | CASP7; MAPT; HSD17B10 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.047E-03 | 7.241E-03 | CYP1A2; CYP1B1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.493E-04 | 4.559E-03 | CYP1A2; CYP3A4 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.438E-04 | 3.171E-03 | CA2; CA4 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.116E-03 | 1.351E-02 | CASP1; NFKB1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.083E-03 | 1.691E-02 | CYP1A2; CYP3A4 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.208E-03 | 2.401E-02 | CYP1B1; NFKB1; MCL1 |
hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 2.659E-03 | 1.576E-02 | CASP1; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.260E-03 | 1.691E-02 | CA2; CYP3A4 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.645E-03 | 3.173E-02 | CASP7; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 4.743E-03 | 2.316E-02 | CASP1; NFKB1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.986E-03 | 2.615E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
C00-D49: Neoplasms | Cancer | C00-C96 | CA9; NFKB1; MCL1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; AKR1B1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
NA: NA | Edema | NA | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |